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 Whether multiple prothrombotic genotypes reduce bleeding risk during anticoagulation in 
patients with venous thromboembolism (VTE) is unknown 
 
 The five genotypes most strongly associated with VTE risk were assessed in 676 incident 
VTE cases 
 
 An increasing number of prothrombotic risk alleles was not associated with major 
bleeding risk  
 
 Prothrombotic genotypes may not help to stratify major bleeding risk during 





Background: Genotypes associated with venous thromboembolism (VTE) may protect against 
bleeding due to a hypercoagulable state. Whether the risk of major bleeding is reduced in parallel 
with an increasing number of prothrombotic genotypes during anticoagulant treatment in VTE 
remains unknown.  
Objectives: To investigate the association between multiple prothrombotic genotypes and risk of 
major bleeding in patients with VTE.  
Methods: Patients with incident VTE (n=676) derived from the Tromsø Study were genotyped 
for rs6025 (F5), rs1799963 (F2), rs8176719 (ABO), rs2066865 (FGG) and rs2036914 (F11) 
single nucleotide polymorphisms (SNPs). Major bleeding events were recorded during the first 
year after VTE according to the International Society on Thrombosis and Haemostasis criteria. 
Cox-regression was used to calculate hazard ratios with 95% confidence intervals (CIs) for major 
bleeding adjusted for age, sex and duration of anticoagulation according to individual 
prothrombotic SNPs and categories of risk alleles (5-SNP score; 0-1, 2, 3 and ≥4). 
Results: In total, 50 patients experienced major bleeding (incidence rate: 9.5/100 person-years, 
95% CI 7.2–12.5). The individual SNPs and number of risk alleles were not associated with 
major bleeding risk. The hazard ratios for major bleeding per category increase of genetic risk 
score were 1.0 (95% CI 0.8-1.3) for the total study population and 1.1 (95% CI 0.8-1.5) when 
patients with active cancer were excluded. Analyses restricted to the first 3 months after VTE 
yielded similar results. 
Conclusion: Our findings suggest that an increasing number of prothrombotic risk alleles is not 
protective against major bleeding in VTE patients during anticoagulation.    
 




Bleeding is a dominant and potentially serious complication in patients undergoing anticoagulant 
treatment for venous thromboembolism (VTE).
1
 The annual rates of major bleeding (MB) in 
VTE patients during anticoagulant treatment have been reported to vary from 1% to 
approximately 10% depending on the type of anticoagulant, patient characteristics and study 
setting (clinical trials versus daily care).
2-7
 An accurate risk prediction of MB is crucial to make 
informed decisions on VTE management and particularly to guide the treatment duration in 
unprovoked VTE towards the highest net benefit. However, the current prediction models for MB 
in VTE are mainly based on clinical factors, and do not discriminate well between VTE patients 
at high and low risk of MB in validation studies.
8-11
 Extended knowledge on risk factors 
associated with MB in VTE patients is a key step to improve risk stratification of MB events 
during anticoagulant treatment.  
Single nucleotide polymorphisms (SNPs) associated with increased risk of VTE, such as 
factor V Leiden (FVL), prothrombin G20210A, and non-O blood type,
12
 could be plausible 
candidate risk factors for MB. The prothrombotic genotypes have been shown to be associated 
with a hypercoagulable state
12
 and could therefore have the potential to counteract the risk of 
bleeding related to anticoagulation in VTE patients. For instance, FVL is associated with 
resistance to the natural anticoagulant protein C,
13
 prothrombin G20210A with increased plasma 
levels of prothrombin,
14
 and non-O blood type with increased plasma levels of von Willebrand 
factor and coagulation factor VIII.
15
 The few studies addressing the impact of prothrombotic 
genotypes on the risk of MB during anticoagulant therapy have suggested a decreased risk of MB 
in carriers of FVL
16
 and non-O blood types.
17
 
In the context of VTE, de Haan and colleagues developed a genetic risk score originally 





 The number of prothrombotic risk alleles included in the genetic score was dose-
dependently associated with VTE risk (i.e. the more risk alleles present, the higher the risk of 
VTE). A similar predictive performance and dose-response relationship was found when the 
authors conceived a more parsimonious score consisting of the 5 most strongly VTE-associated 
SNPs, i.e. rs6025 (FVL) in F5, rs1799963 (prothrombin G20210A) in F2, rs8176719 (non-O 
blood type) in ABO, rs2066865 in the fibrinogen gamma gene (FGG) and rs2036914 in F11.
18
 
Given that the mechanisms by which multiple prothrombotic genotypes affect the thrombosis risk 
likely reflect different pathways in blood coagulation, we hypothesized that an increasing number 
of prothrombotic risk alleles would have a dose-dependent protective effect on the risk of MB. 
To the best of our knowledge, no previous study has assessed the impact of multiple 
prothrombotic genotypes on the risk of MB. Therefore, we aimed to investigate the association 





The study population originated from the Tromsø Study, a single-center, population-based 
prospective cohort, with repeated health surveys of the inhabitants of Tromsø, Norway.
19
 Study 
participants were recruited from the fourth (1994-1995), fifth (2001-2002) and sixth (2007-2008) 
surveys of the Tromsø Study. The overall attendance rates were high, achieving 77% in the fourth 
survey, 79% in the fifth survey, and 66% in the sixth survey. In total, there were 30 371 unique 
individuals aged 25-97 years who participated in at least one of the surveys. The study was 
approved by the Regional Committee of Research and Medical Health Ethics, and all study 
participants provided informed written consent.  
 
 6 
From the date of inclusion in one of the three surveys until the end of follow-up at 
December 31, 2012, all potential first lifetime venous thromboembolism (VTE) events were 
identified by searching the hospital discharge diagnosis registry, the autopsy registry, and the 
radiology procedure registry at the University hospital of North Norway (UNN). Identified cases 
were adjudicated by trained personnel and deemed as validated when signs and symptoms of 
deep vein thrombosis (DVT) or pulmonary embolism (PE) were combined with objective 
confirmation by radiological procedures, and resulted in a VTE diagnosis requiring treatment, as 
described in detail previously.
20
 A total of 737 objectively confirmed VTE cases were identified 
during follow-up. Of these, 45 did not have blood samples available or of sufficient quality for 
DNA analysis, and 16 were not successfully genotyped for one or more of the SNPs of interest. 
Therefore, 676 VTE cases were included in our study. 
 
Clinical characteristics of VTE events 
Information on clinical and provoking factors at the time of and 12 weeks preceding the VTE 
diagnosis was obtained for all eligible patients by review of medical records at the UNN. In the 
case of a concurrent DVT and PE diagnosis, the VTE event was classified as a PE. Each VTE 
event was further classified as provoked if one or more of the following risk factors were present: 
major surgery, trauma or acute medical conditions (acute myocardial infarction, ischemic stroke, 
or major infectious disease) within 12 weeks prior to VTE event, marked immobilization (bed 
confinement > 3 days, wheel-chair, or long distance travel exceeding 4 hours within the last 14 
days prior to VTE event), or any other factor specifically described in the medical records to have 
provoked the VTE (e.g. intravascular catheter). Presence of known active cancer at the time of 
VTE diagnosis was regarded as a provoked VTE.  
 
 7 
To account for type and duration of VTE treatment, we considered the planned treatment 
(i.e. heparin or vitamin k antagonist [VKA]) and duration of anticoagulation that were stated by 
the attending physicians in the medical records at the time of VTE diagnosis. Duration of 
anticoagulant therapy was categorized into 3, 6, 12, and more than 12 months, as previously 
described.
21
          
 
Assessment of major bleeding (MB) events 
The medical records for all participants were searched for MB events occurring during the 365 
days following the VTE. All second-line care and advanced emergency medicine, such as 
transfusion of blood products, is exclusively provided by the UNN. The UNN is situated in the 
middle of Tromsø municipality, with a vicinity of approximately 250 kilometers to the nearest 
hospital providing comparable health-care functions. Two reviewers (trained medical personnel 
from the UNN) adjudicated the bleeding events independently in accordance with the criteria 
proposed by the International Society on Thrombosis and Hemostasis (ISTH).
22
 In short, a 
bleeding event that was fatal, and/or symptomatic in a critical area or organ, and/or causing a fall 
in hemoglobin level of ≥20 g/L, or requiring transfusion of ≥2 units of whole blood or red blood 
cells, was considered major. In case of disagreement, the event was discussed in an endpoint 
committee (HSJ and JBH) to reach consensus. 
 
Genotyping and quality control 
Blood samples were collected from an antecubital vein at enrollment in the Tromsø Study and the 
initial preparation of samples was done at the department of Clinical Chemistry at the UNN. 
DNA was isolated from whole blood and stored at -70 C at the national CONOR biobank, 
located at the HUNT Biobank in Levanger, Norway. As previously described,
23
 we genotyped 
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rs6025 (FVL) in F5, rs1799963 (prothrombin G20210A) in F2, rs8176719 (non-O blood type) in 
ABO and rs2036914 in F11 with the Sequenom platform, and rs2066865 in FGG with the 
TaqMan platform. For Sequenom, which uses single-base extension followed by mass 
spectrometry to measure the molecular mass of the extended primer, samples were genotyped 
with the Sequenom iPlex Gold Assay according to the recommended protocol, with an initial 
input of 10-20 ng of DNA, and were analyzed with the MassARRAY Analyzer 4. Only 
genotypes with a high quality score of “A - Conservative” or “B - Moderate” were used. When 
multiple attempts were made to genotype an individual, one of the highest-quality genotypes 
across all attempts was chosen for each SNP. For TaqMan, an initial input of 100 ng of DNA was 
used. Samples were genotyped with the Applied Biosystems 7900HT (Foster City, CA, USA) 
according to the recommended protocol, and processed with SDS 2.4 (Thermo Fisher, Foster 
City, CA, USA).   
Subjects were considered carriers of the prothrombotic risk gene when one or two risk 
alleles were present. Individual SNP assessment was done without differentiation between 
heterozygous and homozygous carriers due to small number of homozygotes for most SNPs. 
According to literature, risk alleles were defined as the variant associated with increased VTE 
risk.
12,18
 Among the SNPs studied, rs2036914 in F11 was the only one with a minor allele 
associated with reduced VTE risk, and in this case, we considered the common allele as the risk 
allele. Similar to de Haan et al., a 5‐ SNP score was conceived by counting the number of risk 
alleles from the five sequenced SNPs, with a theoretical maximum number of ten risk alleles for 







Subjects were followed from the date of their first lifetime VTE to the date of an incident MB, 
death, migration, or end of follow-up (i.e. 365 days after the first VTE), whichever came first.  
Subjects who died or migrated out of the municipality of Tromsø were censored at the date of the 
respective event. Statistical analyses were performed using STATA version 15.0 (Stata 
Corporation LP, College Station, TX, USA).   
Based on the 5-SNP score, we created categories of 0-1, 2, 3 and  4 risk alleles instead of 
performing analyses per-risk-allele, due to small numbers. Crude incidence rates (IRs) with 95% 
confidence intervals (CIs) of MB were calculated for the individual SNPs and categories of the 5-
SNP score, and expressed as number of events per 100 person-years at risk. Cox proportional 
hazards regression models were used to calculate hazard ratios (HRs) with 95% CIs for MB 
according to the individual SNPs (reference: 0 risk allele) and categories of the 5-SNP score 
(reference: 0-1 risk allele). HRs were adjusted for age and sex in a first model with the addition 
of planned duration of anticoagulant therapy in a second model. Risk estimates were adjusted for 
treatment duration because knowledge of thrombophilia or family history of early VTE onset 
might have resulted in the admitting physician planning longer treatment with anticoagulation, 
which could affect the risk of MB. In a separate sensitivity analysis, we also calculated HRs for 
MB by risk alleles restricted to the first three months after VTE diagnosis, when all subjects 
would be on anticoagulant treatment. For further sensitivity purposes, we assessed the risk of MB 
after excluding subjects with known cancer at time of VTE diagnosis, as cancer patients might be 
at increased risk of bleeding during anticoagulation.
24
 Finally, we performed subgroup analyses 
according to clinical presentation (i.e. DVT or PE) and presence of provoking risk factors (i.e. 
provoked or unprovoked VTE events). The proportional hazard assumption was assessed by 
evaluating the parallelism of the log-log survivor function by categories of number of risk alleles, 
and tested with Schoenfeld residuals.  
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The 1-year cumulative incidences of MB across categories of the 5-SNP score were 
calculated and visualized in one minus Kaplan-Meier (1-KM) plots for the overall population and 
after excluding those with cancer at the time of VTE diagnosis.    
 
Results 
Baseline characteristics according to categories of prothrombotic risk alleles derived from the 5-
SNP score are shown in Table 1. In the study population, the mean age and body mass index, the 
proportion of DVT and PE, and the planned duration of anticoagulation did not substantially 
differ across categories of risk alleles. Among patients in the highest category of the genetic score 
(i.e. ≥ 4 risk alleles), the proportion of men, subjects with active cancer at the time of VTE 
diagnosis and those treated with heparin tended to be lower, and the VTE events were more likely 
to be unprovoked in comparison with patients in the other categories.  
Among the 676 patients with incident VTE, 50 had an MB within 1 year after the VTE 
event, resulting in an overall IR of 9.5 per 100 person-years (95% CI 7.2-12.5). The median time 
from incident VTE to MB was 33 days (interquartile range 11-180 days). Characteristics of MB 
events are presented in Table 2, showing that nearly half of the MB episodes was classified as 
major due to symptomatic bleeding in a critical area or organ. 
As depicted in Fig. 1, the distribution of VTE patients across number of prothrombotic 
risk alleles of the 5-SNP score ranged from 0 to 6, with a median number of 3. The IRs and HRs 
for MB according to individual SNPs and categories of risk alleles of the 5-SNP score in the 
overall population are shown in Table 3. None of the individual SNPs were associated with risk 
of MB. In the age- and sex-adjusted models, HRs for MB were within the range 1.0 to 1.1 for 
rs6025 (F5), rs8176719 (ABO), and rs2066865 (FGG). Further adjustment for planned duration 
of anticoagulation did not materially change risk estimates. For rs2036914 in F11, the HR for 
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MB was 2.0 (95% CI 0.8-5.0) in the fully adjusted model, and for rs1799963 in F2, no individual 
carrying ≥1 risk allele experienced MB. Similarly to the individual SNPs, the number of 
prothrombotic risk alleles in the 5-SNP score had no impact on the risk of MB (Table 3). In the 
model adjusted for age, sex, and planned duration of anticoagulation, the HR for MB per 
category increase of genetic risk score was 1.0 (95% CI 0.8-1.3). Compared to subjects with 0-1 
risk allele, the HRs for MB were 1.7 (95% CI 0.7-4.5), 1.6 (95% CI 0.6-4.0) and 1.3 (95% CI 0.5-
3.5) in carriers of 2, 3 and ≥4 risk alleles, respectively. When analyses were restricted to the first 
3 months of follow-up, again there was no consistent association of the individual SNPs or 
categories of the 5-SNP score with risk of MB (Supplementary Table 1).  
In sensitivity analysis, in which we excluded patients with known active cancer at the 
time of VTE diagnosis, results were essentially similar to the main analysis, with no significant 
associations between prothrombotic genotypes and risk of MB (Table 4). Table 5 shows the risk 
of MB by categories of the 5-SNP score according to subgroups of VTE (provoked, unprovoked, 
DVT and PE). For unprovoked VTE, the HR for MB per category increase of genetic risk score 
was 1.0 (95% CI 0.6-1.6) in the fully adjusted model. Analyses of the other subgroups did not 
reveal any consistent association of MB risk across number of prothrombotic risk alleles.   
The 1-year cumulative incidences of MB across categories of the 5-SNP score were 
estimated by 1-KM for the overall study population (Fig. 2A) and after excluding subjects with 
active cancer at the time of VTE diagnosis (Fig. 2B). As shown in Fig. 2A, the majority of the 
MB events occurred in the first 3 months after the VTE. The 3-month cumulative incidences of 
MB for subjects with 0-1, 2, 3 and ≥4 risk alleles were 2.0% (95% CI 0.5-7.9), 6.6% (95% CI 
3.7-11.5), 6.7%, (95% CI 3.9-11.2), and 4.1% (95% CI 2.0-8.5), respectively. Similar results 





In this population-based cohort of 676 patients followed for 1 year after their first lifetime VTE, 
we investigated whether the risk of MB was stepwise reduced in parallel with an increasing 
number of prothrombotic risk alleles. Using a genetic risk score based on five prothrombotic 
SNPs, we found that the number of risk alleles was not associated with risk of MB. Likewise, 
none of the individual prothrombotic SNPs were associated with risk of MB. Exclusion of 
patients with active cancer at the time of VTE diagnosis, restriction to the first 3 months after 
VTE diagnosis, or subgroup analyses stratified by unprovoked or provoked VTE and location 
(i.e. DVT or PE) yielded essentially similar results. Our findings suggest that a hypercoagulable 
state driven by prothrombotic genotypes is not able to restrain a severe bleeding associated with 
anticoagulant treatment.  
In our study, originated from the general population, the overall rate of MB was 9.5 per 
100 person-years, which was considerably higher than the rate of about 1.0 per 100 person-years 
reported in randomized controlled trials (RCTs) comprising VTE patients.
2
 However, our results 
are not unexpected, as unselected patients derived from the general population have more often 
serious comorbidities and are managed under less intensive surveillance as compared to patients 
selected into RCTs. Moreover, RCTs on the efficacy and safety of anticoagulant treatment tend to 
exclude patients with a bleeding predisposition. Of note, 24% of our patients (159 out of 676) had 
active cancer at the time of VTE diagnosis, which is a well-known risk factor for bleeding during 
anticoagulation.
24
 Our rate of MB is in line with a similar prospective cohort consisting of 842 
VTE patients treated with anticoagulant therapy during daily care, of whom 21.5% had known 
cancer.
7
 In the above mentioned study, the rate of MB was 10.6 per 100 person-years, and it was 
especially high in analysis restricted to VTE patients with cancer (15.7 per 100 person-year). 
Another noteworthy finding of our study was the fact that the majority of the MB events occurred 
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within the first 3 months after VTE. These results are in accordance with previous data
25
 and with 
the notion that patients with an underlying predisposition to bleeding are more likely to develop a 
MB event early after initiation of anticoagulation. Still, the prothrombotic genotypes studied were 
not associated with risk of MB even within the initial 3 months after VTE when the majority of 
MB events occurred.  
The association between prothrombotic genotypes and risk of MB has been scarcely 
investigated in a VTE population under anticoagulant treatment.
16,17
 In a Dutch case-control 





 found that the risk of MB during anticoagulation with VKAs in non-OO blood 
group carriers was 30% lower than in carriers of OO blood group. Even though risk estimates 
pointed towards a protective effect (odds ratios = 0.7, 95% CI 0.4-1.1), the 95% CIs were 
somehow wide and included unity in the aforementioned report.
17
 Furthermore, only 20% of 110 
cases with MB and 220 controls without MB presented VTE as an indication for anticoagulation, 
and bleeding leading to hospitalization was also among the criteria to define MB.
17,26
 Admission 
to hospital can be influenced by other important factors, such as support in the community and 
presence of comorbidities,
22
 thus not necessarily reflecting the severity of a bleeding event. In 
another study, Franchini et al. assessed the ABO blood group phenotypes instead of genotypes in 
183 cases with bleeding complications and 366 controls without bleeding during treatment with 
VKA, of whom about 25% had VTE.
27
 Even though bleeders met at most grade 2 (mild blood 
loss) of a 4-grade World Health Organization grading system, no association between ABO blood 
group and bleeding was found.
27
 Our results interpreted in light of the existing studies indicate 
that there are no consistent data supporting a protective effect of non-O blood type on the risk of 
MB in VTE patients during anticoagulation.  
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In a study derived from the RIETE-registry comprising 10139 VTE patients tested for 
thrombophilia, Tzoran et al.
16
 investigated the impact of FVL on the risk of MB during 
anticoagulation. Compared to noncarriers, FVL carriers (n = 1384) had a 50% (HR 0.50, 95% 
0.25-0.99) lower risk of MB. It is important to address that patients undergoing thrombophilia 
testing generally do not share the clinical characteristics of unselected VTE patients derived from 
a general population. For instance, in the above mentioned study,
16
 the proportion of VTE 
patients with cancer was relatively low (6%-11% among carriers and noncarriers of the 
prothrombotic genotypes studied) as compared to the present study (24%). Therefore, the study 
from Tzoran et al. is not necessarily comparable to our population-based cohort.   
It is of interest that minor bleeding has been shown to be associated with subsequent 
increased risk of MB in patients treated with VKA, independent of the quality of anticoagulation 
and other known risk factors.
28
 The association was confirmed and further explored by van Rein 
et al.,
29
 who used a case-crossover design to untangle the nature of such an association. Results 
from the case-crossover study suggested that minor bleeds could be markers for fixed risk factors 
for MB events, like genetic variants affecting blood coagulation. For instance, the mild 
hypercoagulable state associated with FVL
13
 has been proposed to have offered evolutionary 
advantages in face of life-threatening bleeding, such as during childbirth, warfare, or other 
activities carrying high risks of trauma.
30
 However, in the context of bleeding related to 
anticoagulant treatment after a VTE, our study revealed that neither the individual SNPs nor the 
increasing number of prothrombotic risk alleles included in the 5-SNP score
18
 were protective 
against an MB event in VTE patients. We can speculate that the mild hypercoagulability driven 
by FVL and the other prothrombotic genotypes would probably not be able to balance the 
mechanisms that induce a MB associated with anticoagulant treatment. Alternatively, our 
findings could be explained by a phenomenon called index event bias.
31
 VTE is a result of 
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multiple risk factors, and a selection of only incident VTE events (as in a cohort of VTE patients) 
may induce dependence between these risk factors. For example, an inverse association between 
carriership of prothrombotic genotypes and other prothrombotic factors could arise in the incident 
VTE population. If these other prothrombotic factors are also protective against bleeding, the 
effect measure of the risk of MB in carriers of prothrombotic genotypes compared to noncarriers 
may be shifted towards the null. Taken together, based on our findings, it is unlikely that the 
prothrombotic genotypes included in the 5-SNP score would be of clinical relevance to improve 
discrimination between those with high and low risk of MB during anticoagulant treatment in 
VTE patients.  
The inclusion of subjects derived from the general population is among the main strengths 
of the present study. In comparison to subjects included in RCTs, the clinical characteristics, 
comorbidities and prevalence of cancer in our study participants are similar to those found in 
real-life patients, thereby increasing the external validity of our results. Other strengths include 
the complete and validated registry of VTE events, the exclusivity of UNN as the sole health care 
provider, likely to receive all relevant MB events, and the strict criteria used to define MB based 
on the ISTH recommendations.
22
 Limitations also need to be addressed. Given our sample size 
and number of MB cases, the statistical power could have been limited to detect slight protective 
effects of prothrombotic genotypes, especially among those in the uppermost category of the 
genetic score (i.e. carriers of ≥4 risk alleles) and in subgroups of VTE. Of note, the risk estimates 
of MB were above 1.0 in some subgroups, but the 95% CIs of these estimates were considerably 
wide and included unity. It is important to address, that when the 5-SNP score was analyzed per 
category increase in genetic risk score, the risk estimates were 1.0 or around 1.0 both in overall 
and subgroup analyses, as well as in sensitivity analyses, thereby suggesting no protective effect 
of prothrombotic genotypes on MB risk in VTE patients. We were not able to perform analyses 
 
 16 
stratified by planned type of anticoagulant treatment (i.e. heparin or heparin and VKA) due to the 
low number of participants in the heparin group (n = 98) and the low number of MB events (n = 
10). Moreover, we did not have information on concomitant use of drugs that might have affected 
the bleeding risk, such as antiplatelet agents. However, it is very unlikely that the type of 
anticoagulant, and the use of concomitant drugs, would differ across categories of prothrombotic 
risk alleles and thereby serve as potential confounders for the relationship between prothrombotic 
genotypes and risk of MB. In this study, we did not have access to information on the actual 
duration of anticoagulant treatment. Nonetheless, when we restricted our analyses to the first 
three months after VTE diagnosis (i.e. a period during which all patients would be on 
anticoagulant treatment), results were essentially similar to the overall analyses, showing no 
consistent association between prothrombotic risk alleles and risk of MB. Finally, an increasing 
number of prothrombotic risk alleles could still be protective against clinically relevant non-
major bleedings (CRNMB). However, our study was not designed to evaluate CRNMB, and 
future research is required to address this question.   
In conclusion, our study suggests that prothrombotic genotypes, evaluated either as 
individual SNPs or as number of risk alleles included in a 5-SNP score, do not protect against 
MB in VTE patients during anticoagulant treatment. Our findings further suggest that assessment 
of prothrombotic genotypes is not helpful to improve patient stratification of MB risk during 
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Tables and figures 
Table 1 Baseline characteristics of venous thromboembolism (VTE) cases across categories of 
the 5-single nucleotide polymorphism (SNP) score 
 Number of risk alleles 
 0-1 
(n = 109) 
2 
(n = 179) 
3 
(n = 205) 
≥ 4 
(n = 183) 
Age (years), mean ± SD 71 ± 12 68 ± 14 69 ± 14 67 ± 13 





, mean ± SD 27.2 ± 4.7 27.1 ± 4.8 27.4 ± 4.6 27.3 ± 4.3 
DVT 56 (61) 56 (101) 59 (121) 57 (104) 
PE ± DVT 44 (48) 44 (78) 41 (84) 43 (79) 
Provoked VTE 63 (69) 63 (112) 57 (117) 51 (94) 
Unprovoked VTE 37 (40) 37 (67) 43 (88) 49 (89) 
Active cancer
b
 27 (29) 28 (50) 25 (52) 15 (28) 
Initial thrombolytic therapy 6 (7) 4 (8) 5 (10) 5 (9) 
Planned treatment type     
   Heparin
c
 16 (17) 18 (32) 15 (30) 10 (19) 
   Heparin and VKA
d 
68 (74) 69 (124) 75 (153) 80 (147) 
Planned duration of 
anticoagulation 
    
   ≤ 3 months 36 (39) 36 (65) 36 (73) 37 (67) 
   > 3 including 6 months 32 (35) 33 (59) 37 (76) 33 (61) 
   > 6 including 12 months 22 (24) 26 (47) 20 (42) 19 (35) 
   > 12 months 10 (11) 5 (8) 7 (14) 11 (20) 
Abbreviations: Body mass index (BMI); DVT, deep vein thrombosis; PE, pulmonary embolism; 
SD, standard deviation; VKA, vitamin K antagonist 
Categorical variables are shown as percentages with numbers in brackets, % (n) 
a




Active cancer at the time of VTE diagnosis  
c
Low molecular weight or unfractionated heparin 
d
Low molecular weight or unfractionated heparin with VKA treatment
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Table 2 Characteristics of major bleeding in patients with venous thromboembolism 
Major bleeding site  % (n) 
   Gastrointestinal  36 (18) 
   Intramuscular/compartment syndrome  24 (12) 
   Intracranial  16 (8) 
   Urogenital   12 (6) 
   Retroperitoneal  6 (3) 
   Other*  6 (3) 
ISTH major bleeding criteria   
   Fatal bleeding †
 
 6 (3) 
   Critical area or organ ‡
 
 46 (23) 
   Blood transfusion § ± hemoglobin fall ¶
 
 48 (24) 
*Pericardial and subcutaneous/hematoma; ISTH, International Society on Thrombosis and 
Haemostasis  
† Fatal outcome within one week after major bleeding 
‡ Intracranial, retroperitoneal, pericardial and intramuscular with compartment syndrome 
§ Bleeding leading to transfusion of ≥ 2 units of whole blood or red cells 















Table 3 Risk of major bleeding (MB) by individual single nucleotide polymorphisms (SNPs) and 
number of prothrombotic risk alleles in patients with venous thromboembolism 
Risk allele MB events (n = 50) IR (95% CI)* HR (95% CI) † HR (95% CI) ‡ 
SNP (gene)     
rs6025 (F5)
 
    
0 43 9.6 (7.1-13.0) Ref.  Ref.  
≥1 7 8.5 (4.1-17.9) 1.0 (0.4-2.2) 1.0 (0.4-2.2) 
rs1799963 (F2)
 
    
0 50 9.7 (7.4-12.8) Ref.  Ref. 
≥1 0 - - - 
rs8176719 (ABO)     
0 17 10.2 (6.3-16.4) Ref. Ref. 
≥1 33 9.1 (6.5-12.8) 1.0 (0.5-1.7) 1.0 (0.5-1.7) 
rs2066865 (FGG)     
0 26 9.1 (6.2-12.4) Ref. Ref. 
≥1 24 9.8 (6.6-14.7) 1.1 (0.7-2.0) 1.2 (0.7-2.0) 
rs2036914 (F11)     
0 5 5.3 (2.2-12.8) Ref. Ref. 
≥1 45 10.4 (7.7-13.9) 2.0 (0.8-5.0) 2.0 (0.8-5.0) 
5-SNP score    
0-1 6 7.0 (3.2-15.7) Ref.  Ref.  
2 15 11.3 (6.8-18.7) 1.7 (0.7-4.5) 1.7 (0.7-4.5) 
3 17 10.8 (6.7-17.4) 1.6 (0.6-4.0) 1.6 (0.6-4.0) 
≥4 12 7.9 (4.5-13.9) 1.3 (0.5-3.5) 1.3 (0.5-3.5) 
Per category increase   1.0 (0.8-1.3) 1.0 (0.8-1.3) 
* IR, incidence rate per 100 person-years; HR, hazard ratio; CI, confidence interval 
† Adjusted for age and sex 




Table 4 Risk of major bleeding (MB) by individual single nucleotide polymorphisms (SNPs) and 
number of prothrombotic risk alleles in patients with venous thromboembolism (VTE) without 
active cancer at the time of VTE diagnosis 
Risk allele MB events (n = 35) IR (95% CI) HR (95% CI) † HR (95% CI) ‡ 
SNP (gene)
 
    
rs6025 (F5)     
0 28 7.5 (5.2-10.9) Ref. Ref. 
≥1
 
7 9.5 (4.5-19.9) 1.5 (0.7-3.5) 1.6 (0.7-3.6) 
rs1799963 (F2)     
0 35 8.1 (5.8-11.3) Ref. Ref. 
≥1 0 - - - 
rs8176719 (ABO)     
0 13 9.6 (5.5-16.5) Ref. Ref. 
≥1 22 7.1 (4.7-10.6) 0.8 (0.4-1.5) 0.8 (0.4-1.5) 
rs2066865 (FGG)     
0 17 7.1 (4.4-11.3) Ref. Ref. 
≥1 18 8.8 (5.5-13.9) 1.3 (0.7-2.5) 1.4 (0.7-2.6) 
rs2036914 (F11)     
0 2 2.6 (0.6-10.4) Ref. Ref. 
≥1 33 8.9 (6.4-12.6) 3.6 (0.9-15.0) 3.5 (0.8-14.7) 
5-SNP score     
0-1 4 5.8 (2.2-15.5) Ref. Ref. 
2 8 7.2 (3.6-14.4) 1.4 (0.4-4.8) 1.4 (0.4-4.7) 
3 14 10.9 (6.5-18.4) 2.0 (0.6-6.0) 2.0 (0.7-6.2) 
≥4 9 6.5 (3.4-12.5) 1.3 (0.4-4.3) 1.3 (0.4-4.4) 
Per category increase   1.1 (0.8-1.5) 1.1 (0.8-1.5) 
* IR, incidence rate per 100 person-years; HR, hazard ratio; CI, confidence interval 
† Adjusted for age and sex 




Table 5 Risk of major bleeding (MB) by number of prothrombotic risk alleles in subgroups of 
venous thromboembolism  
DVT (n=387) MB events  IR (95% CI) HR (95% CI) † HR (95% CI) ‡ 
5-SNP score     
0-1
 
3 6.2 (2.0-19.2) Ref.  Ref. 
2 10 13.9 (7.5-25.8) 2.2 (0.6-8.0) 2.2 (0.6-8.1) 
3 10 10.7 (5.7-19.8) 1.7 (0.5-6.2) 1.7 (0.5-6.2) 
≥4 5 5.7 (2.4-13.1) 1.0 (0.2-4.0) 1.0 (0.2-4.0) 
Per category increase   0.9 (0.6-1.3) 0.9 (0.6-1.3) 
PE (n=289)
 
    
5-SNP score     
0-1 3 8.2 (2.6-25.4) Ref. Ref. 
2 5 8.2 (3.4-19.6) 1.2 (0.3-5.3) 1.3 (0.3-5.5) 
3 7 11.0 (5.3-23.1) 1.5 (0.4-5.7) 1.6 (0.4-6.1) 
≥4 7 10.9 (5.2-22.9) 1.8 (0.5-7.0) 1.9 (0.5-7.6) 
Per category increase   1.2 (0.8-1.8) 1.2 (0.8-1.9) 
Provoked (n=392)     
5-SNP score     
0-1 4 8.2 (3.1-21.7) Ref. Ref. 
2 11 14.6 (8.1-26.4) 2.0 (0.6-6.3) 2.0 (0.6-6.5) 
3 12 15.6 (8.9-27.5) 1.9 (0.6-6.0) 2.0 (0.6-6.2) 
≥4 8 11.5 (5.7-23.0) 1.6 (0.5-5.4) 1.7 (0.5-5.6) 
Per category increase   1.1 (0.8-1.5) 1.1 (0.8-1.5) 
Unprovoked (n= 284)     
5-SNP score     
0-1 2 5.5 (1.4-22.1) Ref. Ref. 
2 4 6.9 (2.6-18.3) 1.4 (0.3-7.9) 1.4 (0.3-7.9) 
3 5 6.2 (2.6-14.9) 1.2 (0.2-6.3) 1.2 (0.2-6.3) 
≥4 4 4.8 (1.8-12.9) 1.0 (0.2-5.6) 1.0 (0.2-5.6) 
Per category increase   1.0 (0.6-1.6) 1.0 (0.6-1.6) 
SNP, single nucleotide polymorphism; DVT, deep vein thrombosis; PE, pulmonary embolism 
* IR, incidence rate per 100 person-years; HR, hazard ratio; CI, confidence interval 
† Adjusted for age and sex 
‡ Adjusted for age, sex and planned duration of anticoagulation  
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Legends to figures  
 
Figure 1. Distribution (%) of patients with incident venous thromboembolism (VTE) across 
number of risk alleles of the 5-single nucleotide polymorphism (SNP) score. 
 
Figure 2. Cumulative incidences (1-Kaplan-Meier) of major bleeding according to categories of 
risk alleles of the 5-single nucleotide polymorphism (SNP) score in overall venous 
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Supplementary material  
Supplementary Table 1 Risk of major bleeding (MB) by individual single nucleotide 
polymorphisms (SNPs) and number of prothrombotic risk alleles during the first three months 
after venous thromboembolism 
Risk allele MB events (n = 33) IR (95% CI) HR (95% CI) † 
SNP (gene)    
rs6025 (F5)
 
   
0 29 23.8 (16.6-34.3) Ref.  
≥1 4 18.0 (6.8-47.9) 0.8 (0.3-2.4) 
rs1799963 (F2)
 
   
0 33 23.5 (16.7-33.0) Ref.  
≥1 0 - - 
rs8176719 (ABO)    
0 9 19.7 (10.3-37.9) Ref. 
≥1 24 24.4 (16.4-36.4) 1.3 (0.6-2.8) 
rs2066865 (FGG)    
0 15 19.3 (11.6-32.0) Ref. 
≥1 18 27.2 (17.1-43.2) 1.5 (0.7-3.0) 
rs2036914 (F11)    
0 3 11.7 (3.8-36.4) Ref. 
≥1 30 25.3 (17.7-36.2) 2.2 (0.7-7.0) 
5-SNP score   
0-1 2 8.2 (2.2-34.6) Ref.  
2 11 29.5 (16.5-53.7) 3.8 (0.8-17.2) 
3 13 29.9 (17.4-51.6) 3.5 (0.8-15.7) 
≥4 7 17.3 (8.2-36.3) 2.2 (0.5-10.7) 
Per category increase   1.1 (0.8-1.5) 
† Adjusted for age and sex 
IR, incidence rate per 100 person-years; HR, hazard ratio; CI, confidence interval 
